ITCA20080017A1 - Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. - Google Patents
Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari.Info
- Publication number
- ITCA20080017A1 ITCA20080017A1 IT000017A ITCA20080017A ITCA20080017A1 IT CA20080017 A1 ITCA20080017 A1 IT CA20080017A1 IT 000017 A IT000017 A IT 000017A IT CA20080017 A ITCA20080017 A IT CA20080017A IT CA20080017 A1 ITCA20080017 A1 IT CA20080017A1
- Authority
- IT
- Italy
- Prior art keywords
- alpha
- linked
- treatment
- cyclodextrin
- diseases
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims description 3
- 208000019553 vascular disease Diseases 0.000 title claims description 3
- 239000002502 liposome Substances 0.000 claims description 12
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 10
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 10
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 9
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims description 8
- 229960000711 alprostadil Drugs 0.000 claims description 8
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 8
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 208000008960 Diabetic foot Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 206010062198 microangiopathy Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
TITOLO
Farmaco a base di liposomi di fosfatidilcolina trasportanti una Prostaglandina E1 legata alla alfaciclodestrina per il trattamento delle microngiopatie diabetiche e altre Patologie vascolari.
DESCRIZIONE
Preparazione delle PGEl-alfa-ciclodestrina liposomiale
1.51 scioglie la fosfatidilcolina in alcool etilico e si preparano dei liposomi del diametro tra i 50nm ed i 200nm con un apparato adatto. Si liofilizzano sotto vuoto i liposomi.
2.51 mettono a contatto 50 pgr di PGE1 legata a 1000 pgr di alfa-ciclodestrina, in soluzione acquosa, con 50 mgr di liposomi liofilizzati.
3.51 liofilizza il tutto per la conservazione nel tempo.
4.51 iniettano in vena, nei pazienti, i 50 mmgr di liposomi contenenti la PGE1 portati a 100 mi con soluzione salina, in un tempo di 24 ore con una pompa elastomerica. Si ripete l'infusione almeno 5 volte a distanza di 5 ÷ 7 giorni.
Claims (6)
- TITOLO Farmaco a base di liposomi di fosfatidilcolina trasportanti una Prostaglandina E1 legata alla alfaciclodestrina per il trattamento delle microngiopatie diabetiche e altre Patologie vascolari. RIVENDICAZIONI 1. Si rivendica un Liposoma caratterizzato dal fatto di contenere PGElpura legata-alfaciclodestrina, per il trattamento delle affezioni tipo Microangiopatia Diabetica.
- 2. Si rivendica un Liposoma caratterizzato dal fatto di contenere PGE1 legata-alfaciclodestrina , per il trattamento delle affezioni tipo Tronbo-Angioite Obliterante o Morbo di Buerger.
- 3. Si rivendica un Liposoma caratterizzato dal fatto di contenere PGE1 legata-alfaciclodestrina, per il trattamento delle microangiopatie nelle Connettivopatie Autoimmuni.
- 4. Si rivendica un Liposoma caratterizzato dal fatto di contenere PGE1 legata-alfaciclodestrina, per il trattamento delle affezioni tipo Piede diabetico
- 5. Si rivendica un Liposoma caratterizzato dal fatto di contenere PGpl legata-alfaciclodestrina, per il trattamento delle affezioni tipo impotenza erigendi postprostatectomia.
- 6. Si rivendica un Liposoma caratterizzato dal fatto di contenere PGE1 legata-alfaciclodestrina, per il trattamento delle affezioni arteriose da ipprco|£Sterolemia allo stadio iniziale.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000017A ITCA20080017A1 (it) | 2008-07-31 | 2008-07-31 | Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000017A ITCA20080017A1 (it) | 2008-07-31 | 2008-07-31 | Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ITCA20080017A1 true ITCA20080017A1 (it) | 2010-02-01 |
Family
ID=40512420
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT000017A ITCA20080017A1 (it) | 2008-07-31 | 2008-07-31 | Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | ITCA20080017A1 (it) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4054736A (en) * | 1970-06-10 | 1977-10-18 | Ono Pharmaceutical Co., Ltd. | Clathrate compounds of prostaglandins or their analogues with cyclodextrin |
| EP0758645A1 (en) * | 1995-08-16 | 1997-02-19 | Ono Pharmaceutical Co., Ltd. | Prostaglandin derivatives |
| CN1478540A (zh) * | 2003-03-20 | 2004-03-03 | 蔡海德 | 一种治疗糠尿病及其并发症和病毒性肝炎的组合药物及其制备方法 |
| US20060247317A1 (en) * | 2005-03-04 | 2006-11-02 | Sucampo Ag | Method for treating peripheral vascular diseases |
| CN1915222A (zh) * | 2006-09-18 | 2007-02-21 | 蔡海德 | 一种脂质体组合物及其制备方法 |
-
2008
- 2008-07-31 IT IT000017A patent/ITCA20080017A1/it unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4054736A (en) * | 1970-06-10 | 1977-10-18 | Ono Pharmaceutical Co., Ltd. | Clathrate compounds of prostaglandins or their analogues with cyclodextrin |
| EP0758645A1 (en) * | 1995-08-16 | 1997-02-19 | Ono Pharmaceutical Co., Ltd. | Prostaglandin derivatives |
| CN1478540A (zh) * | 2003-03-20 | 2004-03-03 | 蔡海德 | 一种治疗糠尿病及其并发症和病毒性肝炎的组合药物及其制备方法 |
| US20060247317A1 (en) * | 2005-03-04 | 2006-11-02 | Sucampo Ag | Method for treating peripheral vascular diseases |
| CN1915222A (zh) * | 2006-09-18 | 2007-02-21 | 蔡海德 | 一种脂质体组合物及其制备方法 |
Non-Patent Citations (4)
| Title |
|---|
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 2005, CAI, HAIDE: "Medical composition for treating diabetes mellitus and its complication and viral hepatitis and its preparation", XP002523255, retrieved from STN Database accession no. 2005:5405 * |
| DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 27 February 2007 (2007-02-27), CAI, HAIDE: "Method for preparing liposome composition containing aspirin and prostaglandin", XP002523254, retrieved from STN Database accession no. 2007:208377 * |
| K. PARFITT: "Martindale 32th edition", 2000, PHARMACEUTICAL PRESS, LONDON, XP002523252 * |
| R.C. ROWE, P.J. SHESKEY, P.J. WELLER: "Handbook of pharmaceutical excipients, fourth edition", 18 June 2003, PHARMACEUTICAL PRESS, LONDON, XP002523253 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL263296A (en) | Extracellular bubbles originating from human platelet crises for medical use | |
| Reddy | Mobilization and collection of peripheral blood progenitor cells for transplantation | |
| US9622968B2 (en) | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries | |
| US8618056B2 (en) | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries | |
| EP2391341A2 (en) | Resuscitation fluid | |
| US10716756B2 (en) | Compositions and methods for reducing reperfusion injury | |
| WO2012096697A1 (en) | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries | |
| ITCA20080017A1 (it) | Farmaco a base di liposomi di fosfatidilcolina trasportanti una prostaglandina e1 legata alla alfa-ciclodestrina per il trattamento delle microngiopatie diabetiche e altre patologie vascolari. | |
| JP2016519101A (ja) | オメガ−３脂肪酸およびトマトリコペンを含む抗炎症性相乗的組み合わせ | |
| EP0088022B1 (fr) | Agents antitumoraux à efficacité améliorée, leur obtention et procédé pour augmenter l'efficacité des agents antitumoraux | |
| WO2012104568A1 (en) | Compositions of monoterpenoids for stimulating the immune system | |
| CN1155384C (zh) | 环糊精包合前列腺素e1冻干粉针制剂及生产工艺 | |
| US20040091506A1 (en) | Topical antifungal treatment | |
| US20190015327A1 (en) | Compositions and methods for treating conditions related to lack of blood supply, shock and neuronal injuries | |
| Veroux et al. | Efficacy of a novel method of intravenous infusion of the prostaglandin analogue iloprost for the treatment of lower-limb critical ischemia: an open-label, nonrandomized study in two cohorts | |
| WO2014026121A1 (en) | Methods and compositions for treating conditions related to lack of blood supply, shock and neuronal injuries | |
| Hodgson et al. | Augmented potentiation of renal vasoconstrictor responses by thromboxane A2 receptor stimulation in the alloxan‐diabetic rat | |
| JP2015535258A5 (it) | ||
| Hoffman et al. | Central cardiovascular activity of prostaglandin E2, prostagladin F2∝ and prostacyclin | |
| CN110520147A (zh) | 用于治疗铁过载的组合物和方法 | |
| FR2703252A1 (fr) | Complexe immunomodulateur anti SIDA. | |
| US6710081B1 (en) | Erection insufficiency remedies | |
| Gorbacheva et al. | New peptide PAR1-agonist demonstrates neuroprotective effect on ischemia injury | |
| CN101244278A (zh) | 一种可供静脉注射的双氯芬酸钠注射用制剂及其制备方法 | |
| JP2016521678A (ja) | 幹細胞の腫瘍形成能の抑制方法 |